Revenue Recognition and Collaborative Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue Recognition and Collaborative Arrangements
Net revenue	$ 108,220	$ 100,806	$ 198,279	$ 186,324
GSK | Royalty revenue from a related party
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	111,676	104,262	205,191	193,236
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)	(6,912)	(6,912)
Net revenue	108,220	100,806	198,279	186,324
GSK | RELVAR/BREO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	59,326	65,916	115,090	122,306
GSK | ANORO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	9,630	11,960	18,072	22,460
GSK | TRELEGY
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	$ 42,720	$ 26,386	$ 72,029	$ 48,470